SALT LAKE CITY, Utah–(OrthoSpineNews)– Kolosis BIO, LLC (Kolosis), a pure-play biologics company and an exclusive bone graft partner to MTF Biologics, announced today its 2022 results and 2023 expectations. The company nearly doubled its revenue in 2022, driven by the continued success of its flagship product, Kore Fiber, and its pre-hydrated DBM tissue-form, Prime HD.
“We are thrilled with the success we achieved in 2022,” said Collin Begley, CEO of Kolosis. “The expanded market adoption of Kore Fiber and the continued strong performance of Prime HD have been major drivers of our success. We are committed to continuing our focus on innovation and developing game-changing, disruptive technologies in 2023.”
Kolosis President, Keegan Begley, added, “Our value proposition in the market as a pure-play biologics company is extremely compelling with our best-in-class aseptically processed technologies from MTF and rapidly expanding contract access for our bone graft portfolio. We have made considerable advancements in the area of research and providing clinical evidence for our existing products, and we expect to see significant publications and developments in the coming year.”
Kolosis anticipates strong revenue growth in 2023 as it continues to expand its sales force, novel product offering, and scientific evidence for its technologies.
Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.
As the company looks to the future, Kolosis is committed to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit www.kolosis.com.
Maxwell Hunter –Chief Operating Officer